Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial

Vasc Health Risk Manag. 2013:9:535-49. doi: 10.2147/VHRM.S44568. Epub 2013 Sep 27.

Abstract

Background: The aim of this study was to compare the antihypertensive efficacy of losartan 100 mg + hydrochlorothiazide (HCTZ) 25 mg versus bisoprolol 10 mg + HCTZ 25 mg and their influence on arterial stiffness and central blood pressure (BP).

Methods: Of 60 patients with a mean BP of 173.3 ± 1.7/98.4 ± 1.2 mmHg, 59 were randomized to losartan + HCTZ (n = 32) or bisoprolol + HCTZ (n = 27). Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months. Body mass index, office and 24-hour ambulatory BP, pulse wave velocity (carotid-femoral [PWVE] and radial [PWVM]), noninvasive central systolic BP, augmentation index (AIx), laboratory investigations, and electrocardiography were done at baseline and after 6 months of treatment.

Results: Losartan + HCTZ was as effective as bisoprolol + HCTZ, with target office BP achieved in 96.9% and 92.6% of patients and target 24-hour BP in 75% and 66.7% of patients, respectively, after 6 months. Effective treatment of BP led to significant lowering of central systolic BP, but this was decreased to a significantly (P < 0.05) greater extent by losartan + HCTZ (-23.0 ± 2.3 mmHg) than by bisoprolol + HCTZ (-15.4 ± 2.9 mmHg) despite equal lowering of brachial BP. Factors correlated with central systolic BP and its lowering differed between the treatment groups. Losartan + HCTZ did not alter arterial stiffness patterns significantly, but bisoprolol + HCTZ significantly increased AIx. We noted differences in ΔPWVE, ΔPWVM, and ΔAIx between the groups in favor of losartan + HCTZ. Decreased heart rate was associated with higher central systolic BP and AIx in the bisoprolol + HCTZ group, but was not associated with increased AIx in the losartan + HCTZ group.

Conclusion: Although both treatments decreased both office and 24-hour BP, losartan + HCTZ significantly decreased central systolic BP and had a more positive influence on pulse wave velocity, with a less negative effect of decreased heart rate on AIx and central systolic BP.

Keywords: arterial hypertension; arterial stiffness; central blood pressure; combination therapy.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-1 Receptor Antagonists / administration & dosage*
  • Amlodipine / administration & dosage
  • Angiotensin II Type 1 Receptor Blockers / administration & dosage*
  • Antihypertensive Agents / administration & dosage*
  • Bisoprolol / administration & dosage*
  • Blood Pressure / drug effects*
  • Blood Pressure Monitoring, Ambulatory
  • Calcium Channel Blockers / administration & dosage
  • Chi-Square Distribution
  • Diuretics / administration & dosage*
  • Doxazosin / administration & dosage
  • Drug Combinations
  • Drug Therapy, Combination
  • Electrocardiography
  • Female
  • Heart Rate / drug effects
  • Humans
  • Hydrochlorothiazide / administration & dosage*
  • Hypertension / diagnosis
  • Hypertension / drug therapy*
  • Hypertension / physiopathology
  • Losartan / administration & dosage*
  • Male
  • Middle Aged
  • Pulse Wave Analysis
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome
  • Ukraine
  • Vascular Stiffness / drug effects

Substances

  • Adrenergic beta-1 Receptor Antagonists
  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Diuretics
  • Drug Combinations
  • bisoprolol, hydrochlorothiazide drug combination
  • hydrochlorothiazide, losartan drug combination
  • Hydrochlorothiazide
  • Amlodipine
  • Losartan
  • Doxazosin
  • Bisoprolol